Paroxysmal Nocturnal Hemoglobinuria (PNH)
What is Paroxysmal Nocturnal Hemoglobinuria (PNH)?
Paroxysmal nocturnal hemoglobinuria is a rare blood disorder that destroys red blood cells. The condition happens when the immune system's complement proteins attack red blood cells that lack protective surface proteins. This destruction process is called hemolysis and it releases hemoglobin into the bloodstream and urine.
PNH develops from a genetic mutation in bone marrow stem cells. The mutation prevents cells from making proteins that normally shield them from complement attack. As these mutated stem cells multiply, they produce vulnerable red blood cells that get destroyed prematurely. The name comes from the dark urine that can occur at night due to red cell breakdown.
This condition affects approximately 1 to 5 people per million worldwide. While PNH can occur at any age, it most commonly appears in people during their 30s and 40s. The severity varies widely from person to person. Some people have mild symptoms while others experience life-threatening complications.
Symptoms
- Dark or tea-colored urine, especially in the morning
- Extreme fatigue and weakness
- Shortness of breath during normal activities
- Pale skin and mucous membranes
- Rapid heart rate or chest pain
- Difficulty swallowing or abdominal pain
- Headaches and confusion
- Back pain or flank pain
- Blood clots in unusual locations
- Erectile dysfunction in men
Some people with PNH have mild symptoms that develop slowly over months or years. Others may not notice symptoms until a hemolytic crisis occurs. The severity and frequency of symptoms depend on how many affected red blood cells are present.
Concerned about Paroxysmal Nocturnal Hemoglobinuria (PNH)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
PNH is caused by an acquired mutation in the PIGA gene within bone marrow stem cells. This mutation is not inherited from parents but occurs spontaneously during a person's lifetime. The damaged gene prevents cells from making GPI-anchor proteins that normally protect red blood cells from immune system attack. Without this protection, complement proteins destroy the cells.
Risk factors for developing PNH include having aplastic anemia or myelodysplastic syndrome. These bone marrow disorders create an environment where mutated stem cells may have a survival advantage. Stress, infections, surgery, and certain medications can trigger hemolytic episodes in people who already have PNH. Physical exertion, alcohol consumption, and hormonal changes may also worsen symptoms. The condition affects men and women equally across all ethnic backgrounds.
How it's diagnosed
Doctors diagnose PNH primarily through flow cytometry, a specialized test that detects red blood cells lacking protective surface proteins. Blood tests also reveal signs of hemolysis including elevated bilirubin levels from red cell breakdown. Red Cell Distribution Width measures variation in red blood cell size, which increases during chronic hemolysis. Urine tests may show urobilinogen and hemoglobin during active hemolytic episodes.
Rite Aid's testing panel includes bilirubin, RDW, and urine urobilinogen to help monitor disease activity and hemolysis. These biomarkers track how actively red blood cells are being destroyed. Your doctor may order additional specialized tests to confirm the diagnosis and assess disease severity. Regular monitoring helps guide treatment decisions and catch complications early.
Treatment options
- Complement inhibitor medications like eculizumab or ravulizumab to prevent red cell destruction
- Folic acid supplements to support red blood cell production
- Iron supplementation if chronic urinary iron loss causes deficiency
- Blood transfusions during severe anemia or hemolytic crises
- Anticoagulation therapy to prevent or treat blood clots
- Bone marrow transplant in severe cases, the only potential cure
- Avoiding triggers like infections, stress, and certain medications
- Vaccinations against meningococcal bacteria before starting complement inhibitors
- Regular monitoring of blood counts and kidney function
- Staying hydrated to protect kidney function during hemolysis
Concerned about Paroxysmal Nocturnal Hemoglobinuria (PNH)? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Paroxysmal means sudden and recurring. Nocturnal refers to nighttime, when hemolysis was thought to be worse. Hemoglobinuria means hemoglobin in the urine, which creates dark-colored urine. The name describes episodes of red blood cell breakdown that release hemoglobin into urine.
During sleep, breathing slows and blood becomes slightly more acidic. This acidic environment activates complement proteins that destroy vulnerable red blood cells. The released hemoglobin passes through kidneys into urine overnight, creating the characteristic dark morning urine. Not everyone with PNH experiences this symptom.
PNH is not inherited from parents, even though it involves a genetic mutation. The PIGA gene mutation happens spontaneously in bone marrow stem cells during a person's lifetime. You cannot pass PNH to your children because the mutation only affects blood cells, not reproductive cells.
PNH involves the immune system's complement proteins actively destroying red blood cells. Most other anemias result from nutritional deficiencies, chronic disease, or inadequate production. PNH also carries a high risk of blood clots in unusual locations like abdominal veins. This clotting risk makes PNH particularly dangerous compared to typical anemias.
Yes, several blood tests show signs of active hemolysis in PNH. Bilirubin rises when red blood cells break down and release their contents. RDW increases due to size variation in red blood cells. Urine urobilinogen elevates during hemolytic episodes, confirming active cell destruction.
Complement inhibitors block specific complement proteins that attack red blood cells in PNH. These medications prevent the immune system from destroying vulnerable cells, reducing hemolysis dramatically. Eculizumab and ravulizumab are the main drugs used. They require lifelong treatment and vaccination against meningococcal infection before starting.
When red blood cells rupture, they release substances that activate clotting pathways. Free hemoglobin also consumes nitric oxide, which normally keeps blood vessels relaxed and prevents clotting. PNH patients face 40 times higher clot risk than the general population. Clots can occur in unusual locations like liver or brain veins.
PNH rarely goes into spontaneous remission, though disease severity can vary over time. Bone marrow transplant is currently the only potential cure. However, transplant carries significant risks and is typically reserved for severe cases. Most people manage PNH long-term with complement inhibitor medications.
Testing frequency depends on disease severity and treatment status. People on complement inhibitors typically need monitoring every 3 to 6 months. Those with unstable disease may require monthly testing. Regular blood work tracks hemolysis markers like bilirubin and RDW to guide treatment adjustments.
Stay well-hydrated to protect kidneys during hemolytic episodes. Avoid known triggers like certain infections, excessive alcohol, and unnecessary medications. Get recommended vaccinations to prevent infections that could worsen hemolysis. Manage stress through adequate sleep and gentle exercise as tolerated.